All In Biotech

Investigational drug · Phase 2

RSV vaccine candidate

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus Infection, Healthy Volunteers, Respiratory Syncytial Virus Immunization.

Phase 2

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

19

Any phase or sponsor naming "RSV vaccine candidate"

First trial start

2022

Nov 17, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RSV vaccine candidate", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Respiratory Syncytial Virus Infection
  • Healthy Volunteers
  • Respiratory Syncytial Virus Immunization

Approved drugs for the same conditions: RSV · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "RSV vaccine candidate" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 68 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.